BlackRock Advisors’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

BlackRock Advisors’s Portfolio MNTA Stock Details MNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$509K	Buy	33,815 +466	+1%	+$6.16K	﹤0.01%	2198
2016 Q3	$390K	Sell	33,349 -56,912	-63%	-$669K	﹤0.01%	2308
2016 Q2	$975K	Sell	90,261 -64,246	-42%	-$663K	﹤0.01%	1773
2016 Q1	$1.43M	Sell	154,507 -2,819	-2%	-$30.3K	﹤0.01%	1584
2015 Q4	$2.33M	Sell	157,326 -13,247	-8%	-$222K	﹤0.01%	1351
2015 Q3	$2.8M	Buy	170,573 +6,566	+4%	+$134K	﹤0.01%	1261
2015 Q2	$3.74M	Buy	164,007 +90,887	+124%	+$1.81M	﹤0.01%	1069
2015 Q1	$1.11M	Buy	73,120 +5,303	+8%	+$68.9K	﹤0.01%	1496
2014 Q4	$817K	Sell	67,817 -182,055	-73%	-$2.08M	﹤0.01%	1624
2014 Q3	$2.83M	Sell	249,872 -364	-0.1%	-$4.15K	﹤0.01%	1090
2014 Q2	$3.02M	Buy	250,236 +31,100	+14%	+$367K	﹤0.01%	1076
2014 Q1	$2.55M	Sell	219,136 -213,843	-49%	-$3.62M	﹤0.01%	1118
2013 Q4	$7.66M	Sell	432,979 -87,673	-17%	-$1.47M	0.01%	882
2013 Q3	$7.49M	Buy	520,652 +33,753	+7%	+$517K	0.01%	869
2013 Q2	$7.33M	Buy	+486,899	New	+$6.43M	0.01%	861

Other funds holding MNTA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BlackRock Advisors's MNTA Position: Q4 2016 in Review

BlackRock Advisors increased its Momenta Pharmaceuticals, Inc. (MNTA) stake by 1.4% in Q4 2016, buying an estimated $6.16K and bringing the position to 33,815 shares worth $509K. The position accounts for ﹤0.01% of the portfolio, ranked #2198.

BlackRock Advisors first reported a position in MNTA in Q2 2013 and has held it in 15 quarters since. The position peaked at $7.66M in Q4 2013. 160 funds tracked by Wall St. Rank hold MNTA as of Q4 2016.

BlackRock Advisors held 33,815 shares of Momenta Pharmaceuticals, Inc. worth $509K as of Q4 2016.
BlackRock Advisors bought 466 Momenta Pharmaceuticals, Inc. shares in Q4 2016, an estimated $6.16K.
Momenta Pharmaceuticals, Inc. made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #2198 holding.
BlackRock Advisors first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2013 and has held it in 15 quarters since.
BlackRock Advisors's Momenta Pharmaceuticals, Inc. position peaked at $7.66M in Q4 2013.
160 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.